Treating hypothyroidism is not always easy: When to treat subclinical hypothyroidism, TSH goals in the elderly, and alternatives to levothyroxine monotherapy

被引:15
|
作者
Ross, Douglas S. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Thyroid Associates, Endocrine Div, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
levothyroxine and liothyronine combined therapy; subclinical hypothyroidism; QUALITY-OF-LIFE; THYROID-HORMONE THERAPY; L-THYROXINE THERAPY; DOUBLE-BLIND; THYROTROPIN ASSAY; COGNITIVE FUNCTION; SERUM THYROTROPIN; PLUS LIOTHYRONINE; RANDOMIZED-TRIAL; INCREASED RISK;
D O I
10.1111/joim.13410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The majority of patients with hypothyroidism feel better when levothyroxine treatment restores thyroid-stimulating hormone (TSH) concentrations to normal. Increasingly, a significant minority of patients remain symptomatic and are dissatisfied with their treatment. Overzealous treatment of symptomatic patients with subclinical hypothyroidism may contribute to dissatisfaction among hypothyroidism patients, as potential hypothyroid symptoms in patients with minimal hypothyroidism rarely respond to treatment. Thyroid hormone prescriptions have increased by 30% in the United States in the last decade. The diagnosis of subclinical hypothyroidism should be confirmed by repeat thyroid function tests ideally obtained at least 2 months later, as 62% of elevated TSH levels may revert to normal spontaneously. Generally, treatment is not necessary unless the TSH exceeds 7.0-10 mIU/L. In double-blinded randomized controlled trials, treatment does not improve symptoms or cognitive function if the TSH is less than 10 mIU/L. While cardiovascular events may be reduced in patients under age 65 with subclinical hypothyroidism who are treated with levothyroxine, treatment may be harmful in elderly patients with subclinical hypothyroidism. TSH goals are age dependent, with a 97.5 percentile (upper limit of normal) of 3.6 mIU/L for patients under age 40, and 7.5 mIU/L for patients over age 80. In some hypothyroid patients who are dissatisfied with treatment, especially those with a polymorphism in type 2 deiodinase, combined treatment with levothyroxine and liothyronine may be preferred.
引用
收藏
页码:128 / 140
页数:13
相关论文
共 6 条
  • [1] Subclinical Hypothyroidism in the Elderly: To Treat or Not to Treat?
    Mooradian, Arshag D.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (06) : 477 - 486
  • [2] Overt and Subclinical Hypothyroidism in the Elderly: When to Treat?
    Calsolaro, Valeria
    Niccolai, Filippo
    Pasqualetti, Giuseppe
    Calabrese, Alessia Maria
    Polini, Antonio
    Okoye, Chukwuma
    Magno, Silvia
    Caraccio, Nadia
    Monzani, Fabio
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [3] Subclinical hypothyroidism: When to treat
    Azim, Sidra
    Nasr, Christian
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2019, 86 (02) : 101 - 110
  • [4] Subclinical Hypothyroidism in Children: Natural History and When to Treat
    Bona, Gianni
    Prodam, Flavia
    Monzani, Alice
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2013, 5 : 23 - 28
  • [5] Thyroid Related Quality of Life in Elderly with Subclinical Hypothyroidism and Improvement on Levothyroxine is Distinct from that in Young Patients (TSAGE)
    Recker, Stefanie
    Voigtlaender, Richard
    Viehmann, Anja
    Dunschen, Karin
    Kerp, Helena
    Frank-Raue, Karin
    Leidig-Bruckner, Gudrun
    Graf, Dieter
    Lederbogen, Sebastian
    Dietrich, Johannes W.
    Goerges, Rainer
    Brabant, Georg
    Voelker, Uwe
    Watt, Torquil
    Zwanziger, Denise
    Moeller, Lars Christian
    Fuehrer, Dagmar
    HORMONE AND METABOLIC RESEARCH, 2019, 51 (09) : 568 - 574
  • [6] The different outcomes in the elderly with subclinical hypothyroidism diagnosed by age-specific and non-age-specific TSH reference intervals: a prospectively observational study protocol
    Zhang, Xueqi
    Li, Yang
    Jin, Jing
    Wang, Huangman
    Zhao, Bozun
    Wang, Songwen
    Shan, Zhongyan
    Teng, Weiping
    Teng, Xiaochun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14